Biotech ETFs: How Do FBT and IBB Match Up on Cost, Structure, and Performance?

First Trust NYSE Arca Biotechnology Index Fund (FBT) and iShares Biotechnology ETF (IBB) offer different approaches to biotech sector exposure. FBT uses a concentrated 30-stock portfolio with higher returns (53.2% one-year, 168% ten-year) but greater risk, while IBB provides broader diversification with 248 holdings and lower fees (0.44% vs 0.55%). FBT has outperformed IBB over the past decade despite higher concentration risk.

07/12/2026, 3:30 PM • The Motley Fool

BBH vs. XPH: Which Healthcare ETF Is Better for Beginners?

The article compares two healthcare ETFs: VanEck Biotech ETF (BBH) with 25 concentrated holdings and State Street SPDR S&P Pharmaceuticals ETF (XPH) with 65 diversified holdings. Both charge identical 0.35% expense ratios and offer 0.50% dividend yields, but XPH delivered significantly higher 1-year returns (64.30% vs 33.30%) and lower volatility, making it potentially more suitable for beginners seeking diversification.

07/08/2026, 7:28 AM • The Motley Fool

The Dow Couldn't Keep Up With Chip Stocks on Monday

Chip stocks led a Monday rally, with the Nasdaq Composite gaining 1.3% and the S&P 500 rising 0.7%, while the Dow Jones remained flat. Broadcom surged 4.4% after extending its Apple chip supply deal through 2031, and AMD jumped 8% on autonomous driving adoption. However, Microsoft fell 1.4% following announcements of 4,800 job cuts, and the Dow was weighed down by declines in Honeywell and Amgen.

07/06/2026, 2:29 PM • The Motley Fool

Alphabet Just Joined the Dow Jones Industrial Average. 3 Dow Dividend Stocks to Buy Now.

Alphabet joined the Dow Jones Industrial Average on June 29, replacing Verizon. While Alphabet is a strong company with growing cloud and AI segments, its low dividend yield (0.3%) makes it less suitable for income investors. The article recommends three alternative Dow dividend stocks: Cisco Systems, Coca-Cola, and Amgen, all offering stronger dividend yields and solid year-to-date performance.

06/30/2026, 6:05 AM • The Motley Fool

Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?

The article compares Amgen, an established pharmaceutical giant with $36.7B in revenue and strong profitability, against Iovance Biotherapeutics, an emerging biotech firm with innovative cancer therapies showing 60.6% revenue growth but still unprofitable. The author recommends Amgen for 2026 due to its stability, dividend, and proven track record, while acknowledging Iovance's compelling science but noting its execution risks and negative cash flow.

06/23/2026, 7:33 PM • The Motley Fool

Cutaneous Lupus Erythematosus Market to Expand at a CAGR of 8% During the Forecast Period (2026–2036) Amid Emerging Therapies and Increasing Healthcare Investments | DelveInsight

The cutaneous lupus erythematosus (CLE) market is projected to grow at 8% CAGR through 2036, driven by emerging targeted therapies and increased disease awareness. The market was valued at USD 650 million in 2025 across seven major markets. Key pipeline drugs from major pharmaceutical companies targeting plasmacytoid dendritic cells and type I interferon pathways are expected to transform treatment options for CLE patients.

06/22/2026, 1:00 PM • GlobeNewswire

AbbVie Reports Promising New Clinical Updates. Here's What It Means for the Company's Dividend.

AbbVie presented 21 clinical presentations on blood cancer therapies at the European Hematology Association Congress, showcasing progress in its oncology portfolio which generated $6.7 billion in 2025 revenue. The company's diversified pipeline across immunology, oncology, and neuroscience is helping offset Humira's patent-driven decline and could support future dividend growth through expanded cash flow.

06/12/2026, 6:15 AM • The Motley Fool

President Trump Loaded Up on Eli Lilly in Q1. Should You Buy the Obesity Drug Stock Too?

President Trump's Q1 2026 financial disclosures revealed significant purchases of Eli Lilly stock, a major player in the booming anti-obesity drug market. The article cautions investors against simply copying political trades, emphasizing that investment decisions should be based on business fundamentals rather than celebrity or political endorsements. Eli Lilly's obesity treatments Mounjaro and Zepbound generated over $30 billion in combined sales in 2025, with analysts projecting the global anti-obesity drug market could exceed $95-200 billion. While Lilly maintains a strong competitive position with manufacturing advantages and a robust pipeline, its premium valuation already reflects years of future growth, presenting significant downside risk if sales slow or competition intensifies.

05/27/2026, 2:02 PM • The Motley Fool

AI Bots Crashed $10K in 2 Weeks While This ’Beat-the-Bot’ Divvie Sails Higher

A startup experiment showed that eight leading AI bots (Claude, ChatGPT, Gemini, Grok, and others) lost 33% of their $10,000 seed capital in just two weeks through overtrading and poor decision-making. In contrast, dividend-focused investing in blue-chip biotech stocks like Amgen has delivered steady returns, demonstrating that traditional dividend growth strategies outperform AI-driven trading approaches.

05/27/2026, 5:22 AM • Investing

My Personal Plan to Turn Market Chaos Into 300%+ Growth

The article presents a dividend-focused investment strategy combining dollar-cost averaging (DCA) with the 'Dividend Magnet' concept—the tendency for dividend growth to pull share prices higher over time. The strategy involves regular investments, reinvesting dividends, and deploying extra cash during market dips. Two examples are provided: Visa, which has grown dividends 378% over a decade with aggressive buybacks, and Amgen, which shows more volatility relative to its dividend growth, offering more buying opportunities.

05/26/2026, 5:13 AM • Investing

CytomX Therapeutics to Present at Upcoming June Investor Conferences

CytomX Therapeutics announced that management will participate in the Jefferies Global Healthcare Conference on June 4, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026. The company will host fireside chats and one-on-one investor meetings at both events. CytomX is a clinical-stage biopharmaceutical company developing conditionally activated masked PROBODY therapeutics for oncology, with lead candidates including varsetatug masetecan (Varseta-M) for colorectal cancer and CX-801 for melanoma.

05/21/2026, 8:00 AM • GlobeNewswire

Eli Lilly Stock: Next Stop $2,000?

Eli Lilly's stock has surged above $1,000 following strong Q1 results driven by its dominance in weight-loss and diabetes markets. Despite increasing competition from rivals like Novo Nordisk and Amgen, the company maintains advantages through superior pipeline candidates like Retatrutide and diversified revenue streams in oncology, immunology, and neuroscience. AI-powered drug development efforts could further accelerate growth, potentially enabling the stock to double within six years.

05/18/2026, 6:30 PM • The Motley Fool

Amgen Japanese Partner Urges Caution On Tavneos Use

Kissei Pharmaceutical, Amgen's Japanese partner, has urged healthcare professionals to exercise caution with Tavneos (avacopan), advising against prescribing to new patients and reassessing current treatments. This follows FDA warnings in March about serious liver injuries and an April proposal to withdraw approval citing data integrity issues, manipulated clinical trial results, and lack of proven effectiveness. The European Medicines Agency is also reviewing Phase 3 trial data integrity concerns.

05/18/2026, 11:18 AM • Benzinga

Oligonucleotides Clinical Trial Drug Development Pipeline Expands with Contributions from 200+ Key Companies | DelveInsight

The oligonucleotides clinical trial landscape is expanding rapidly with 200+ companies developing 600+ pipeline drugs. Major players like Novartis, Alnylam Pharmaceuticals, Amgen, and WaVe Life Sciences are advancing promising therapies across various clinical stages. Approximately 20+ oligonucleotides are in late-stage development while 150+ are in mid and early stages. Recent developments include SanegeneBio's $110M Series B funding, FDA approvals for multiple orphan drug designations, and several companies advancing Phase II and Phase III trials.

05/14/2026, 1:00 PM • GlobeNewswire

Global Colorectal Cancer Diagnostics and Therapeutics Market Anticipates Impressive Growth Trajectory at a CAGR of ~9% by 2034 | DelveInsight

The global colorectal cancer diagnostics and therapeutics market is projected to grow from USD 35 billion in 2025 to USD 73 billion by 2034 at a CAGR of ~9%. Growth is driven by rising colorectal cancer prevalence, increased screening awareness, advancements in non-invasive diagnostics (liquid biopsy, stool-based DNA tests), and emerging targeted therapies and immunotherapies. North America leads with 41% market share, while Asia-Pacific is the fastest-growing region.

05/13/2026, 1:00 PM • GlobeNewswire